Gentian Diagnostics (GENT) Q2 2024 earnings summary

Executive summary

• Sales revenue reached NOK 38.3 million in Q2 2024, up 12% year-over-year, with 13% organic growth; H1 2024 revenue was NOK 76.8 million, up 17% year-over-year (16% organic growth).

• EBITDA for Q2 2024 was NOK 6.8 million, more than doubling from NOK 3.1 million last year; H1 2024 EBITDA was NOK 11.6 million, over triple the prior year.

• Gross margin improved to 57% in Q2 2024, up from 53% last year, driven by favorable product mix and integration of Getica AB.

• Major milestone achieved with completion of NT-proBNP optimization phase, advancing product pipeline.

• Announced key hires: new CEO Matti Heinonen (starting October 2024) and CTO Frank Frantzen (starting August 2024).

Financial highlights

• Net profit for Q2 2024 was NOK 4.7 million, up from NOK 0.9 million in Q2 2023; H1 2024 net profit was NOK 8.9 million.

• Cash and cash equivalents stood at NOK 81 million as of June 30, 2024; no interest-bearing debt.

• Free cash flow was NOK -4.6 million in Q2 2024, mainly due to working capital changes.

• Equity ratio improved to 84.2% in Q2 2024.

• Approximately 76% of sales revenue in the quarter came from long-term contracts.

Outlook and guidance

• Strong sales momentum expected to continue across all products, excluding China where uncertainty remains due to tendering changes.

• NT-proBNP assay to be introduced as research-use-only in H2 2025; full commercial launch subject to regulatory clearance timelines.

• Full implementation of KDIGO guidelines for Cystatin C could increase market demand 4–5x over the next 4–5 years.

• Targets annual revenue growth of 20%+ for established products, with gross margin ambitions of 60%+ and long-term EBITDA margins of 40%.

• Serviceable market estimated at USD 1.8 billion, with 5–10% annual growth expected over the next 4–6 years.